In terms of product sales, RIGL has been a one drug company with Tavalisse in immune thrombocytopenia. The recent approval of Rezlidhia opens the door for investors to track the growth of another drug, a new source of excitement.

Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023

Use these tips for trading penny stocks right now The post Don't Invest in Penny Stocks Until You've Read This Article appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Don't Invest in Penny Stocks Until You've Read This Article

The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.

Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia

Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for its leukemia treatment. Specifically, the FDA has approved REZLIDHIA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation.

Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News

Shares of Rigel Pharmaceuticals Inc. RIGL, +1.86% soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia treatment. With trading volume of 5.2 million shares, the stock was the most active ahead of the open.

Rigel stock soars after FDA approves leukemia treatment, 2 days after receiving delisting notice

Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing small molecule drugs that enhance the lives of patients with hematologic disorders, cancer, and rare immune diseases. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, its other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.